SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Bernie Sanders joined two other senators in blocking Obama's nomination for FDA chief. (Photo: Gage Skidmore/flickr/cc)
Sanders Puts Block on Obama's Big Pharma Nominee for FDA
'We need someone who will work to substantially lower drug prices, implement rules to safely import brand-name drugs from Canada and hold companies accountable who defraud our government.'
Jan 26, 2016
Senator Bernie Sanders put a hold on President Barack Obama's nominee to take over the Food and Drug Administration (FDA) on Tuesday, joining with two other senators who have also objected to Dr. Robert M. Califf's nomination, citing his ties to corporate drug manufacturers.
"Dr. Califf's extensive ties to the pharmaceutical industry give me no reason to believe that he would make the FDA work for ordinary Americans, rather than just the CEOs of pharmaceutical companies," Sanders said in a statement on Tuesday. "We need someone who will work to substantially lower drug prices, implement rules to safely import brand-name drugs from Canada and hold companies accountable who defraud our government."
As a researcher at Duke University, Califf took millions in funding and "consultation fees" from pharmaceutical giants like Eli Lilly, Merck, and Novartis. The New York Times once described him as the "ultimate industry insider."
Sanders joins Sens. Ed Markey (D-Mass.) and Lisa Murkowski (R-Alaska) in halting Califf's nomination. Markey, who intervened late last week, said he would continue the blockade until the FDA changes its approval process for opioid painkillers, citing the agency's decision to use OxyContin to treat children as young as 11.
Recent measures to combat rising heroin use in U.S. suburbs and rural areas have highlighted the link between prescription medication and drug addiction.
On Tuesday, Sanders also cautioned that the trend of over-prescribing drugs has come in tandem with the price gouging of life-saving medications for millions.
"I share Sen. Markey's concerns that the FDA must change the way it approaches addiction. Too many Americans are dying from what has become an opioid epidemic," Sanders said.
Califf became deputy commissioner at the FDA in 2015. In October, Sanders said he would vote against his nomination, stating, "At a time when millions of Americans cannot afford to purchase the prescription drugs they need, we need a new leader at the FDA who is prepared to stand up to the pharmaceutical companies and work to substantially lower drug prices. Unfortunately, I have come to the conclusion that Dr. Califf is not that person."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Nadia Prupis
Nadia Prupis is a former Common Dreams staff writer. She wrote on media policy for Truthout.org and has been published in New America Media and AlterNet. She graduated from UC Santa Barbara with a BA in English in 2008.
Senator Bernie Sanders put a hold on President Barack Obama's nominee to take over the Food and Drug Administration (FDA) on Tuesday, joining with two other senators who have also objected to Dr. Robert M. Califf's nomination, citing his ties to corporate drug manufacturers.
"Dr. Califf's extensive ties to the pharmaceutical industry give me no reason to believe that he would make the FDA work for ordinary Americans, rather than just the CEOs of pharmaceutical companies," Sanders said in a statement on Tuesday. "We need someone who will work to substantially lower drug prices, implement rules to safely import brand-name drugs from Canada and hold companies accountable who defraud our government."
As a researcher at Duke University, Califf took millions in funding and "consultation fees" from pharmaceutical giants like Eli Lilly, Merck, and Novartis. The New York Times once described him as the "ultimate industry insider."
Sanders joins Sens. Ed Markey (D-Mass.) and Lisa Murkowski (R-Alaska) in halting Califf's nomination. Markey, who intervened late last week, said he would continue the blockade until the FDA changes its approval process for opioid painkillers, citing the agency's decision to use OxyContin to treat children as young as 11.
Recent measures to combat rising heroin use in U.S. suburbs and rural areas have highlighted the link between prescription medication and drug addiction.
On Tuesday, Sanders also cautioned that the trend of over-prescribing drugs has come in tandem with the price gouging of life-saving medications for millions.
"I share Sen. Markey's concerns that the FDA must change the way it approaches addiction. Too many Americans are dying from what has become an opioid epidemic," Sanders said.
Califf became deputy commissioner at the FDA in 2015. In October, Sanders said he would vote against his nomination, stating, "At a time when millions of Americans cannot afford to purchase the prescription drugs they need, we need a new leader at the FDA who is prepared to stand up to the pharmaceutical companies and work to substantially lower drug prices. Unfortunately, I have come to the conclusion that Dr. Califf is not that person."
Nadia Prupis
Nadia Prupis is a former Common Dreams staff writer. She wrote on media policy for Truthout.org and has been published in New America Media and AlterNet. She graduated from UC Santa Barbara with a BA in English in 2008.
Senator Bernie Sanders put a hold on President Barack Obama's nominee to take over the Food and Drug Administration (FDA) on Tuesday, joining with two other senators who have also objected to Dr. Robert M. Califf's nomination, citing his ties to corporate drug manufacturers.
"Dr. Califf's extensive ties to the pharmaceutical industry give me no reason to believe that he would make the FDA work for ordinary Americans, rather than just the CEOs of pharmaceutical companies," Sanders said in a statement on Tuesday. "We need someone who will work to substantially lower drug prices, implement rules to safely import brand-name drugs from Canada and hold companies accountable who defraud our government."
As a researcher at Duke University, Califf took millions in funding and "consultation fees" from pharmaceutical giants like Eli Lilly, Merck, and Novartis. The New York Times once described him as the "ultimate industry insider."
Sanders joins Sens. Ed Markey (D-Mass.) and Lisa Murkowski (R-Alaska) in halting Califf's nomination. Markey, who intervened late last week, said he would continue the blockade until the FDA changes its approval process for opioid painkillers, citing the agency's decision to use OxyContin to treat children as young as 11.
Recent measures to combat rising heroin use in U.S. suburbs and rural areas have highlighted the link between prescription medication and drug addiction.
On Tuesday, Sanders also cautioned that the trend of over-prescribing drugs has come in tandem with the price gouging of life-saving medications for millions.
"I share Sen. Markey's concerns that the FDA must change the way it approaches addiction. Too many Americans are dying from what has become an opioid epidemic," Sanders said.
Califf became deputy commissioner at the FDA in 2015. In October, Sanders said he would vote against his nomination, stating, "At a time when millions of Americans cannot afford to purchase the prescription drugs they need, we need a new leader at the FDA who is prepared to stand up to the pharmaceutical companies and work to substantially lower drug prices. Unfortunately, I have come to the conclusion that Dr. Califf is not that person."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.